QUOTE AND NEWS
Motley Fool  7 hrs ago  Comment 
MannKind's shares dropped by double-digits today. Here's why.
TheStreet.com  7 hrs ago  Comment 
NEW YORK (TheStreet) -- Investors haven't been kind to MannKind  Tuesday following a downgrade from Goldman Sachs to sell from neutral. Analysts also slashed their price target for the stock to $3 from $6. Shares recently fell nearly 9% to...
Benzinga  8 hrs ago  Comment 
In a report published Monday, Goldman Sachs analyst Jay Olson pointed out that the short interest in shares of MannKind Corporation (NASDAQ: MNKD) has "grown high" over the past two years. According to Olson, the rise in short interest can be...
Benzinga  8 hrs ago  Comment 
Goldman Sachs downgraded MannKind Corporation (NASDAQ: MNKD) to a Sell from Neutral, noting that the risk/reward ratio from selling the stock is 55 percent to the downside versus just 5 percent to the upside. The analysts placed a price target of...
Benzinga  10 hrs ago  Comment 
MannKind Corp. (NASDAQ: MNKD) shares dropped 7.83% to $6.12 in pre-market. Goldman Sachs downgraded MannKind from Neutral to Sell and lowered the price target from $6.00 to $3.00. Tarena International, Inc. (NASDAQ: TEDU) fell 6.17% to $10.80...
TheStreet.com  10 hrs ago  Comment 
NEW YORK (TheStreet) -- MannKind was downgraded to a "sell" rating from "neutral" by Goldman Sachs on Tuesday, with the analyst citing the slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for...




 

MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.

Competition

MannKind's primary competitors include:

References

  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki